TMED11 Conference
Shaping Future Healthcare with Clinical Research and Personalised Prescribing
Join us at the historic Guildhall, Derry-Londonderry for the 11th TMED Conference – a leading international event in translational medicine bringing together clinical researchers, academics, industry partners and healthcare innovators from across the UK and Europe.
Poster 29- Real-world outcomes of consolidation durvalumb after chemoradiotherapy in stage III NSCLC: prognostic impact of pan-immune inflammatory value
Authors: Omar Elkhouly, Praveen Baskar, Keerthi Vivekanandan, Saranya Vivekanandan, Raafat Malek
Affiliations: NWCC, Altnagelvin Hospital, Londonderry- BT47 6SB
Background/ Introduction: Consolidation durvalumab following concurrent chemoradiotherapy (CRT) improves survival in unresectable stage III NSCLC; however, robust biomarkers to optimise patient selection remain limited. The pan-immune inflammatory value (PIV), a composite marker of systemic inflammation, has shown prognostic relevance in lung cancer, with elevated levels associated with poorer outcomes. Emerging evidence suggests that dynamic changes in PIV during treatment may outperform static measurements in predicting immunotherapy benefit. We assessed real-world outcomes—including overall survival (OS) and progression-free survival (PFS)—in patients with locally advanced NSCLC treated with durvalumab, and examined the prognostic significance of baseline, pre-immunotherapy, and dynamic PIV.
Material & Methods: We conducted a retrospective study of patients with unresectable stage III NSCLC treated with definitive CRT followed by consolidation durvalumab between 2019 and 2025. OS and PFS were estimated using the Kaplan–Meier method, with log-rank analyses performed according to: Baseline PIV (pre-CRT), Pre-immunotherapy PIV (pre-IO), Dynamic PIV change (ΔPIV: increase vs decrease from pre-CRT to pre-IO).
Results: Thirty-nine patients were included, with a median follow-up of 35 months. Median PFS was 31.2 months, and median OS was 40.2 months. No statistically significant differences in OS or PFS were observed according to baseline PIV, pre-immunotherapy PIV, or dynamic PIV changes.
Conclusion: In this real-world cohort, consolidation durvalumab was associated with favourable survival outcomes compared with those reported in the PACIFIC trial. However, neither static nor dynamic PIV measurements demonstrate significant prognostic value, likely reflecting limited sample size. Larger studies incorporating additional biomarkers are needed to refine patient selection for immunotherapy in stage III NSCLC.
